Activity Description
In less than 30 minutes, you can watch this on-demand, case-based activity from the proceedings of a CE symposium at the 18th Annual Nurse Practitioners in Women’s Health Conference. Learn about:
- The most up-to-date AHA/ACC/TOS, AACE, ENDO, and ANPF obesity guidelines
- The safety and efficacy of FDA-approved weight loss medications
- Collaborating with patients to initiate weight loss medication according to recommended obesity guidelines and the risk profiles of each medication
Learning Objectives
Upon completion of this activity, learners should be able to:
- Summarize the recommendations for obesity management in practice guidelines from AHA/ACC/TOS, AACE, the Endocrine Society, and ANPF
- Evaluate the efficacy and safety data associated with weight-loss strategies, including pharmacotherapy and bariatric surgery
- Collaborate with patients to help them identify weight-loss goals and effective weight-loss strategies
Faculty
Donna H. Ryan, MD, FACP
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Faculty Biography
Donna H. Ryan, MD, FACP
Donna H. Ryan, MD, FACP, is Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, where she directed clinical research for 22 years. Her own research includes participation on the teams that developed and executed the DASH (Dietary Approaches to Stop Hypertension), POUNDS Lost, DPP (Diabetes Prevention Program), and Look AHEAD Studies. Dr Ryan was Principal Investigator for 22 years of a Military Nutrition Grant to develop improvements to soldier readiness, nutrition, and health. Dr Ryan’s continuing research interests focus on translation of effective weight management into primary care practices.
Dr Ryan’s scholarly activities include authorship of more than 200 original publications and 45 books, chapters, and reviews, primarily in the field of obesity. She is Associate Editor-in-Chief for Obesity. She served as Co-Chair of the Expert Panel that produced the AHA/ACC/TOS 2013 Guidelines for the Diagnosis and Management of Obesity and was a panel member of the 2015 Endocrine Society Systematic Evidence Review and Guidelines for Medications That Affect Body Weight.
Disclosure Statements
NPWH policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity.
Conflicts of interest were resolved according to NPWH policy prior to development of content.
NPWH policy requires authors to disclose to the participant when presenting information about unlabeled use of any commercial product or device or an investigational use of a drug or device not yet approved for any use.
Faculty
Donna H. Ryan, MD, FACP
Consultant/Advisory Board: Amgen Inc.; Eisai Inc; Janssen Pharmaceuticals, Inc; Novo Nordisk; Pfizer Inc.; Real Appeal; Takeda Pharmaceuticals U.S.A., Inc; Vivus, Inc.
Speaker Bureau: Eisai Inc; Novo Nordisk; Takeda Pharmaceuticals U.S.A., Inc; Vivus, Inc.
Shareholder: Scientific Intake; Tulip Medical, Ltd.
She does not discuss information related to any non-FDA-approved or investigational use of any product/device.
Educational Planning Committee
Spire Learning
Erin Franceschini, MS, Lauren Waters, and Lisa Conklin have nothing to disclose.
National Association of Nurse Practitioners in Women’s Health
Susan Rawlins, MS, WHNP-BC, NP, has nothing to disclose.
Disclaimer
The participating faculty determines the editorial content of the CE activity and the content does not necessarily represent the views of NPWH or Spire Learning. This content has been peer reviewed for validation of clinical content. While every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with those of established recommendations of other authorities, national guidelines, FDA-approved package inserts, and individual patient characteristics.
Off-Label Statement
This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Levels of Evidence
Strength of recommendations ratings from the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults and the Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline are provided for patient care recommendations made during this activity.
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
| NHLBI Grading of the Strength of Recommendations |
| Grade | Strength of Recommendation |
| A | Strong recommendation There is high certainty based on evidence that the net benefit is substantial. |
| B | Moderate recommendation There is moderate certainty based on evidence that the net benefit is moderate to substantial, or there is high certainty that the net benefit is moderate. |
| C | Weak recommendation There is at least moderate certainty based on evidence that there is a small net benefit. |
| D | Recommendation against There is at least moderate certainty based on evidence that there is no net benefit or that risks/harms outweigh benefits. |
| E | Expert opinion (“There is insufficient evidence or evidence is unclear or conflicting, but this is what the Work Group recommends.”) |
| N | No recommendation for or against (“There is insufficient evidence or evidence is unclear or conflicting.”) |
Source: Jensen MD, et al. Obesity. 2014;22:S1-S410.
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Grade 1: Strong recommendation
Grade 2: Weak recommendation
High quality of evidence (
): Consistent evidence from well performed RCTs or exceptionally strong evidence from unbiased observational studies
Moderate quality of evidence (
): Evidence from RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise evidence), or unusually strong evidence from unbiased observational studies
Low quality of evidence (
): Evidence for at least one critical outcome from observational studies, from RCTs with serious flaws, or indirect evidence
Very low quality of evidence (
): Evidence for at least one of the critical outcomes from unsystematic clinical observations or very indirect evidence
Source: Apovian CM, et al. J Clin Endocrinol Metab. 2015;100:342-362; Swiglo MH, et al. J Clin Endocrinol Metab. 2008;93:666-673.
Target Audience
This activity is designed for healthcare professionals with an interest in the management of obesity in female patients, including Women’s Health Nurse Practitioners, Adult Nurse Practitioners, Family Nurse Practitioners, and Certified Nurse Midwives.
Accreditation
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 0.50 contact hours of continuing education, including 0.50 contact hours of pharmacology content. Each participant should claim only those contact hours actually spent in the educational activity.
Method of Participation
This activity has no fee and should take approximately 30 minutes to complete. Participants should first read the objectives and other introductory CME information, then complete the pre-assessment and participate in the online activity. To receive credit for this activity, participants must complete the post-assessment with a passing score of 70% and then complete the evaluation. This credit is valid through April 14, 2017. No credit will be given after this date. In the event you have questions about this activity or are unable to print the certificate, please e-mail Lauren Waters at lwaters@spirelearning.com, and a certificate will be e-mailed within 2 weeks.
This educational activity is jointly provided by the National Association of Nurse Practitioners in Women’s Health and Spire Learning.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.